DK3494116T3 - Østrogenreceptormodulatorer - Google Patents

Østrogenreceptormodulatorer Download PDF

Info

Publication number
DK3494116T3
DK3494116T3 DK18705097.6T DK18705097T DK3494116T3 DK 3494116 T3 DK3494116 T3 DK 3494116T3 DK 18705097 T DK18705097 T DK 18705097T DK 3494116 T3 DK3494116 T3 DK 3494116T3
Authority
DK
Denmark
Prior art keywords
estrogen
Prior art date
Application number
DK18705097.6T
Other languages
English (en)
Inventor
Johannes Wilhelmus Maria Nissink
Bernard Christophe Barlaam
James Stewart Scott
Samantha Jayne HUGHES
Bin Yang
Thomas Andrew MOSS
Original Assignee
Astrazeneca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca filed Critical Astrazeneca
Application granted granted Critical
Publication of DK3494116T3 publication Critical patent/DK3494116T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK18705097.6T 2017-01-30 2018-01-29 Østrogenreceptormodulatorer DK3494116T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762451971P 2017-01-30 2017-01-30
US201762523695P 2017-06-22 2017-06-22
US201762560304P 2017-09-19 2017-09-19
US201762592485P 2017-11-30 2017-11-30
PCT/EP2018/052040 WO2018138303A1 (en) 2017-01-30 2018-01-29 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
DK3494116T3 true DK3494116T3 (da) 2020-01-27

Family

ID=61223883

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18705097.6T DK3494116T3 (da) 2017-01-30 2018-01-29 Østrogenreceptormodulatorer

Country Status (36)

Country Link
US (3) US10221173B2 (da)
EP (2) EP3689873B1 (da)
JP (1) JP6951451B2 (da)
KR (1) KR102246668B1 (da)
CN (1) CN110214140B (da)
AU (1) AU2018211495B2 (da)
BR (1) BR112019015389A2 (da)
CA (1) CA3050337A1 (da)
CL (1) CL2019001991A1 (da)
CO (1) CO2019008941A2 (da)
CR (1) CR20190379A (da)
CY (1) CY1122731T1 (da)
DK (1) DK3494116T3 (da)
DO (1) DOP2019000183A (da)
EC (1) ECSP19062381A (da)
ES (2) ES2931320T3 (da)
HU (1) HUE047761T2 (da)
IL (1) IL268263B (da)
JO (1) JOP20190183B1 (da)
LT (1) LT3494116T (da)
MA (1) MA52555A (da)
MX (1) MX2019008438A (da)
MY (1) MY196317A (da)
NI (1) NI201900080A (da)
PE (1) PE20191500A1 (da)
PH (1) PH12019501724A1 (da)
PL (1) PL3494116T3 (da)
PT (1) PT3494116T (da)
RS (1) RS59770B1 (da)
SG (1) SG11201906767XA (da)
SI (1) SI3494116T1 (da)
TN (1) TN2020000009A1 (da)
TW (1) TWI794205B (da)
UA (1) UA125043C2 (da)
WO (1) WO2018138303A1 (da)
ZA (1) ZA201904696B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2842579T3 (es) 2016-02-05 2021-07-14 Inventisbio Llc Degradadores de los receptores de estrógenos selectivos y sus usos
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CR20190282A (es) 2016-12-16 2019-08-21 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
TW202126299A (zh) * 2019-09-19 2021-07-16 美商托特斯藥品公司 治療性共軛物
CN115557920B (zh) * 2022-09-22 2024-02-20 吉林奥来德光电材料股份有限公司 一种发光辅助材料、其制备方法及有机电致发光器件

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US7541354B2 (en) 2000-08-10 2009-06-02 Pfizer Italia S.R.L. Bicyclo-pyrazoles
JP5314242B2 (ja) * 2004-04-27 2013-10-16 中外製薬株式会社 プラズマ細胞の増殖方法
JP2008534496A (ja) 2005-03-22 2008-08-28 アストラゼネカ・アクチエボラーグ CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20120157401A1 (en) 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
CA2763485C (en) 2009-05-27 2018-05-15 Neil Almstead Methods for treating cancer and non-neoplastic conditions
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
AU2011264858B2 (en) 2010-06-10 2016-04-21 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
WO2014191726A1 (en) 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
IL287326B2 (en) 2014-12-18 2023-09-01 Hoffmann La Roche Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses
EP3233818A1 (en) 2014-12-18 2017-10-25 F. Hoffmann-La Roche AG Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
CN107531722B (zh) 2015-05-26 2020-07-17 豪夫迈·罗氏有限公司 杂环雌激素受体调节剂及其用途
AU2016279330B2 (en) 2015-06-16 2020-05-14 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
RS62133B1 (sr) 2015-10-01 2021-08-31 Olema Pharmaceuticals Inc Tetrahidro-1h-pirido[3,4-b]indol antiestrogeni lekovi
US10399939B2 (en) 2015-11-09 2019-09-03 Genentech, Inc. Tetrahydronaphthalene estrogen receptor modulators and uses thereof
WO2017080338A1 (zh) 2015-11-12 2017-05-18 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
MX2018007844A (es) 2015-12-22 2019-01-21 Jiangsu Hengrui Medicine Co Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
WO2017174757A1 (en) 2016-04-08 2017-10-12 F. Hoffmann-La Roche Ag Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
JP7064772B2 (ja) 2016-05-06 2022-05-11 ザビエル・ユニバーシティ・オブ・ルイジアナ 選択的エストロゲン受容体ダウンレギュレーター(serds)
WO2018001232A1 (zh) 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
US10149839B2 (en) * 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
ES2975558T3 (es) 2016-09-15 2024-07-09 Arvinas Inc Derivados de indol como degradantes de receptor de estrógeno
CN109843888B (zh) 2016-10-24 2022-03-01 阿斯利康(瑞典)有限公司 可用于治疗癌症的6,7,8,9-四氢-3H-吡唑并[4,3-f]异喹啉衍生物
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PL3555064T3 (pl) 2016-12-16 2023-03-06 Pfizer Inc. Agoności receptora GLP-1 i ich zastosowania
CR20190282A (es) 2016-12-16 2019-08-21 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP2020502117A (ja) 2016-12-16 2020-01-23 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 殺生物剤化合物
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
MA53881A (fr) 2016-12-16 2022-04-27 Lilly Co Eli Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MX2019008895A (es) 2017-01-30 2019-09-13 Chiesi Farm Spa Derivados de amida de tirosina como inhibidores de rho-cinasa.

Also Published As

Publication number Publication date
MY196317A (en) 2023-03-24
KR20190112767A (ko) 2019-10-07
PE20191500A1 (es) 2019-10-22
US10221173B2 (en) 2019-03-05
US20180282325A1 (en) 2018-10-04
PL3494116T3 (pl) 2020-04-30
JP6951451B2 (ja) 2021-10-20
NI201900080A (es) 2020-03-18
JOP20190183B1 (ar) 2022-09-15
CN110214140B (zh) 2022-08-30
UA125043C2 (uk) 2021-12-29
EP3689873A1 (en) 2020-08-05
DOP2019000183A (es) 2019-07-31
JP2020505354A (ja) 2020-02-20
ES2931320T3 (es) 2022-12-28
ZA201904696B (en) 2020-05-27
CY1122731T1 (el) 2021-05-05
TWI794205B (zh) 2023-03-01
PH12019501724A1 (en) 2020-06-01
PT3494116T (pt) 2020-01-28
US20200239468A1 (en) 2020-07-30
HUE047761T2 (hu) 2020-05-28
CO2019008941A2 (es) 2019-08-30
MA52555A (fr) 2021-03-17
LT3494116T (lt) 2020-01-10
EP3494116B1 (en) 2019-10-23
US10590132B2 (en) 2020-03-17
KR102246668B1 (ko) 2021-04-29
CL2019001991A1 (es) 2019-10-11
US20190233413A1 (en) 2019-08-01
US11046689B2 (en) 2021-06-29
CA3050337A1 (en) 2018-08-02
IL268263A (en) 2019-09-26
WO2018138303A1 (en) 2018-08-02
IL268263B (en) 2021-10-31
BR112019015389A2 (pt) 2020-03-10
CN110214140A (zh) 2019-09-06
RS59770B1 (sr) 2020-02-28
ES2766249T3 (es) 2020-06-12
AU2018211495A1 (en) 2019-09-12
SG11201906767XA (en) 2019-08-27
SI3494116T1 (sl) 2020-02-28
TN2020000009A1 (en) 2021-10-04
AU2018211495B2 (en) 2020-05-21
EP3494116A1 (en) 2019-06-12
EP3689873B1 (en) 2022-09-14
MX2019008438A (es) 2019-10-30
CR20190379A (es) 2019-10-21
TW201840558A (zh) 2018-11-16
JOP20190183A1 (ar) 2019-07-28
ECSP19062381A (es) 2019-09-30

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
DE202018003363U8 (de) Handgelenkssphygmomanometer
CL2018000524S1 (es) Golilla
DK3351526T3 (da) Diisopentylterephthalat
DK3568655T3 (da) Rekuperator
DK3494116T3 (da) Østrogenreceptormodulatorer
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
DK3612237T3 (da) Genterapi
DK3568506T3 (da) Offeranode
DK3576686T3 (da) Brokbind
DK3676276T3 (da) Spirothietannukleosider
DK3395159T3 (da) Ballepresse
DK3576718T3 (da) Pastil
FI11704U1 (fi) Liittopuujärjestely
DK3510051T3 (da) Carboxylalkylchitosan
DK3391733T3 (da) Ballepresse
ES1205411Y (es) Maleta-Gaveta
ES1198359Y (es) Columbario
FI11529U1 (fi) Ontelolaatan kannake
DK3645955T3 (da) Buffertank
DK3401461T3 (da) Falsetagtegl
DK3391735T3 (da) Ballepresse
UA37486S (uk) Опакування - етикетка для міні-круасанів
ES1203163Y (es) Cubitera
ES1201836Y (es) Columbario